Get started
Marinus Pharmaceuticals, Inc.Marinus Pharmaceuticals, Inc.Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MRNS chart


Full chart

MRNS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪20.50 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.4681 USD
Net income (FY)
‪−141.41 M‬ USD
Revenue (FY)
‪30.99 M‬ USD
Shares float
‪41.87 M‬
Beta (1Y)
4.12

Employees


Employees (FY)
165
Change (1Y)
+14 +9.27%
Revenue / Employee (1Y)
‪187.81 K‬ USD
Net income / Employee (1Y)
‪−857.00 K‬ USD

About Marinus Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Scott N. Braunstein
Headquarters
Radnor
Website
marinuspharma.com
Founded
2003
FIGI
BBG00253KMF6
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MRNS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MRNS is 0.5275 USD — it has increased by 41.36% in the past 24 hours. Watch Marinus Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Marinus Pharmaceuticals, Inc. stocks are traded under the ticker MRNS.
MRNS stock has risen by 123.40% compared to the previous week, the month change is a 61.54% rise, over the last year Marinus Pharmaceuticals, Inc. has showed a −95.21% decrease.
We've gathered analysts' opinions on Marinus Pharmaceuticals, Inc. future price: according to them, MRNS price has a max estimate of 3.00 USD and a min estimate of 0.30 USD. Watch MRNS chart and read a more detailed Marinus Pharmaceuticals, Inc. stock forecast: see what analysts think of Marinus Pharmaceuticals, Inc. and suggest that you do with its stocks.
MRNS reached its all-time high on Aug 5, 2015 with the price of 82.8800 USD, and its all-time low was 0.2202 USD and was reached on Dec 23, 2024. View more price dynamics on MRNS chart.
See other stocks reaching their highest and lowest prices.
MRNS stock is 31.49% volatile and has beta coefficient of 4.12. Track Marinus Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Marinus Pharmaceuticals, Inc. there?
Today Marinus Pharmaceuticals, Inc. has the market capitalization of ‪20.50 M‬, it has increased by 5.58% over the last week.
Yes, you can track Marinus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Marinus Pharmaceuticals, Inc. is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
MRNS earnings for the last quarter are −0.42 USD per share, whereas the estimation was −0.41 USD resulting in a −2.64% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about Marinus Pharmaceuticals, Inc. earnings.
Marinus Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪8.54 M‬ USD, despite the estimated figure of ‪9.42 M‬ USD. In the next quarter, revenue is expected to reach ‪11.34 M‬ USD.
MRNS net income for the last quarter is ‪−24.23 M‬ USD, while the quarter before that showed ‪−35.83 M‬ USD of net income which accounts for 32.39% change. Track more Marinus Pharmaceuticals, Inc. financial stats to get the full picture.
No, MRNS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 165.00 employees. See our rating of the largest employees — is Marinus Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Marinus Pharmaceuticals, Inc. EBITDA is ‪−122.09 M‬ USD, and current EBITDA margin is −422.52%. See more stats in Marinus Pharmaceuticals, Inc. financial statements.
Like other stocks, MRNS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Marinus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Marinus Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Marinus Pharmaceuticals, Inc. stock shows the sell signal. See more of Marinus Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.